Современная фармакотерапия системного ювенильного артрита
Аннотация
Системный вариант ювенильного артрита (сЮА) входит в число самых тяжелых соматических заболеваний детского возраста. Актуальность проблемы сЮА определяется трудностью ранней диагностики, быстрым развитием инвалидности, неблагоприятным прогнозом с высоким риском развития жизнеугрожающих состояний. Она сохраняется, несмотря на значительные успехи фармакотерапии, позволившие существенно изменить прогноз сЮА. Использование базисных противовоспалительных препаратов (БПВП), а затем и появление генно-инженерных биологических препаратов (ГИБП) принципиально изменили лекарственную модель, применяемую для лечения сЮА. В статье рассмотрены аспекты применения при сЮА различных БПВП и ГИБП с позиций доказательной медицины на основе анализа литературных данных.
Об авторах
И. П. Никишина
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия
Россия
М. И. Каледа
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия
Россия
Список литературы
1. Cassidy JT, et al. Juvenile rheumatoid arthritis. In: Textbook of pediatric rheumatology. Cassidy JT, Petty RE, editors. 4th ed. Philadelphia: W.B. Saunders Company; 2001. P. 218–322.
2. Алексеева ЕИ, Литвицкий ПФ. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников. Под ред. А.А. Баранова. Москва: ВЕДИ; 2007. 368 с. [Alekseeva EI, Litvitskii PF. Yuvenil'nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov [Juvenile rheumatoid arthritis: etiology, pathogenesis, clinical features, diagnosis and treatment algorithms. Guidelines for doctors, teachers, researchers]. Baranov AA, editor. Moscow: VEDI; 2007. 368 p.].
3. Sawhney S, Woo P, Murrey KJ. Macrophage activation syndrome: A potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85(5):421–6. DOI: 10.1136/adc.85.5.421
4. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007 May;34(5):1133–8. Epub 2007 Mar 1.
5. Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27(2):491–6.
6. Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology (Oxford). 2005 Nov;44(11):1350–3. DOI: 10.1093/rheumatology/keh710
7. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7:416–26. DOI: 10.1038/nrrheum.2011.68
8. Truckenbrodt H, Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum. 1986;29(6):801–7. DOI: 10.1002/art.1780290616
9. Speckmaier M, Findeisen J, Woo P, et al. Low-dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol. 1989;7(6):647–50.
10. Giannini EH, Brewer EJ, Kuzmina N, et al, for the Pediatric Rheumatology Collaborative Study Group and the Cooperative Children’s Study Group. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo controlled trial. N Engl J Med. 1992;326(16):1043–9. DOI: 10.1056/NEJM199204163261602
11. Никишина ИП, Родионовская СР. Метотрексат в терапии ювенильного артрита. Пособие для врачей. Москва; 2006 [Nikishina IP, Rodionovskaya SR. Metotreksat v terapii yuvenil'nogo artrita. Posobie dlya vrachei [Methotrexate in the treatment of juvenile arthritis. A guide for physicians]. Moscow; 2006].
12. Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol. 1991;9(3):297–302.
13. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000 Aug;43(8):1849–57. DOI: 10.1002/15290131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F
14. Shaikov АV, Maximov AA, Speransky AI, et al. Repetitive use of pulse therapy with methylprednisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis – preliminary results of a longterm study. J Rheumatol.1992;19(4):612–6.
15. Wallace АA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 1997;40(10):1852–5. DOI: 10.1002/art.1780401019
16. Lehman TJ. Clinical trials for the treatment of systemic onset juvenile rheumatoid arthritis-juvenile idiopathic arthritis. Curr Rheumatol Reports. 2000;2(4):313–5. DOI: 10.1007/s11926000-0068-9
17. Chen CY, Chen LC, Yeh KW, et al. Sequential changes to clinical parameters and adhesion molecules following intravenous pulse cyclophosphamide and methylprednisolone treatment of refractory juvenile idiopathic arthritis. Clin Exper Rheumatol. 2004;22(2):259–64.
18. Gerloni V, Cimaz R, Gattinara M, et al. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology(Oxford). 2001 Aug;40(8):907–13.
19. Ruperto N, Ravelli A, Castell E, et al. Pediatric Rheumatology Collaborative Study Group (PRCSG); Paediatric Rheumatology International Trials Organisation (PRINTO). Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006 Sep-Oct;24(5):599–605.
20. Алексеева ЕИ, Валиева СИ, Апаева ДВ. Эффективность и безопасность комбинированной иммуносупрессивной терапии циклоспорином и метотрексатом у больных тяжелым ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006;5(2 Прил. Ревматические болезни):19–27 [Alekseeva EI, Valieva SI, Apaeva DV. The efficacy and safety of combination immunosuppressive therapy with cyclosporine and methotrexate in patients with severe juvenile rheumatoid arthritis. Voprosy sovremennoi pediatrii. 2006;5(2 Suppl Revmaticheskie bolezni):19–27(In Russ.)].
21. Алексеева ЕИ, Валиева СИ, Апаева ДВ. Эффективность различных режимов иммуносупрессивной терапии циклоспорином и метотрексатом у больных системным вариантом ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2007;6(2):29–34 [Alekseeva EI, Valieva SI, Apaeva DV. The effectiveness of different modes of immunosuppressive therapy with cyclosporine and methotrexate in patients with systemic type of juvenile rheumatoid arthritis. Voprosy sovremennoi pediatrii. 2007;6(2):29–34(In Russ.)].
22. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996 Nov;129(5):750–4. DOI: 10.1016/S0022-3476(96)70160-9
23. Silverman E, Mouy R, Spiegel L, et al for the Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655–66. DOI: 10.1056/NEJMoa041810
24. Foeldvari I, Wierka А. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol. 2010 Aug 1;37(8):1763–7. DOI: 10.3899/jrheum.090874
25. Alcantara AC, Leite CA, Leite AC,et al. A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis. J Rheumatol. 2014 Feb;41(2):338–44. DOI: 10.3899/jrheum.130294
26. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken). 2013;65(10):1551–63. DOI: 10.1002/acr.22087.
27. Lehman TJ, Striegel KH, Onel KB. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr. 2002 Jan;140(1):125–7. DOI: 10.1067/mpd.2002.120835
28. Lehman TJ, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr. 2004;145(6):856–7. DOI: 10.1016/j.jpeds.2004.08.020
29. Brinkman DM, de Kleer IM, ten Cate R, et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum. 2007 Jul;56(7):2410–21. DOI: 10.1002/art.22656
30. Wulffraat NM, van Rooijen EM, Tewarie R, et al. Current perspectives of autologous stem cell transplantation for severe juvenile idiopathic arthritis. Autoimmunity. 2008 Dec;41(8):632–8. DOI: 10.1080/08916930802200224
31. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003 Apr;48(4):1093–101. DOI: 10.1002/art.10885
32. Lovell DJ, Reiff A, Ilowite NT, et al; Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008 May;58(5):1496–504. DOI: 10.1002/art.23427
33. Horneff G, Schmeling H, Biedermann T, et al; Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638–44. DOI:10.1136/ard.2003.014886
34. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005;32(5):935–42.
35. Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol. 2009;36:1078–82. DOI: 10.3899/jrheum.090952
36. Алексеева ЕИ, Алексеева АМ, Бзарова ТМ и др. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006;5(2):20–9 [Alekseeva EI, Alekseeva AM, Bzarova TM, et al. The effectiveness of treatment with infliximab resistant forms of juvenile rheumatoid arthritis. Voprosy sovremennoi pediatrii. 2006;5(2):20–9 (In Russ.)].
37. Алексеева ЕИ, Алексеева АМ, Валиева СИ и др. Влияние инфликсимаба на клинические и лабораторные показатели активности при различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008;7(2):42–54 [Alekseeva EI, Alekseeva AM, Valieva SI, et al. Effect of infliximab on clinical and laboratory indicators of activity in different types of juvenile arthritis. Voprosy sovremennoi pediatrii. 2008;7(2):42–54 (In Russ.)].
38. Ruperto N, Lovell DJ, Quartier P, et al; Paediatric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled withdrawal trial. Lancet. 2008 Aug 2;372(9636):383–91. DOI: 10.1016/S0140-6736(08)60998-8. Epub 2008 Jul 14.
39. Ruperto N, Lovell DJ, Quartier P, et al; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010 Jun;62(6):1792–802. DOI: 10.1002/art.27431
40. Alekseeva E, Valieva S, Denisova R, et al. Efficacy and safety of rituximab for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71(Suppl 3):428. DOI: 10.1136/annrheumdis-2012-eular.2795
41. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998–1006. DOI: 10.1016/S0140-6736(08)60454-7
42. Yokota S, Imagawa T, Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann Rheum Dis. 2009;68(Suppl 3):715.
43. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7(6):R1281–8. DOI: 10.1186/ar1826
44. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–95. DOI: 10.1056/NEJMoa1112802
45. De Benedetti F, Ruperto N, Brunner H, et al. A6: tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER Study. Arthritis Rheum. 2014;66:S8–9. DOI: 10.1002/art.38417
46. De Benedetti F, Ruperto N, Baildam E, et al. A14: Neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2014;66:S23–S24. DOI: 10.1002/art.38422
47. Alexeeva EI, Baranov AA, Denisova RV, et al. Retrospective analysis of efficacy and safety of tocilizumab treatment in patients with severe systemic-onset juvenile idiopathic arthritis followed for 12 months. ISRN Immunology. 2013;2013:548312. DOI: 10.1155/2013/548312
48. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemiconset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747–54. DOI: 10.1136/ard.2010.134254
49. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as firstline disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545–55. DOI: 10.1002/art.30128
50. Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(9):2486–96. DOI: 10.1002/art.38042
51. Ilowite NT, Prather K, Lokhnygina Y, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheum. 2014:2570–9. DOI: 10.1002/art.38699
52. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–406. DOI:
53. 1056/NEJMoa1205099
54. Mü ller K, Herner EB, Stagg A, et al. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Brit J Rheumatol. 1998;37(5):562–9. DOI: 10.1093/rheumatology/37.5.562
55. Carrasco R, Smith JA, Lovell D. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs. 2004;6(3):137–46. DOI: 10.2165/00148581-20040603000001
56. Schmeling H, Mathony K, John V, et al. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis. 2001;60:410–2. DOI: 10.1136/ard.60.4.410
57. Ten Cate R, van Suijlekom-Smit LW, Brinkman DM, et al. Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2002;41(2):228–9. DOI: 10.1093/rheumatology/41.2.228
58. Tynjä lä P, Vä hä salo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of antitumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis. 2009 Apr;68(4):552–7. DOI: 10.1136/ard.2007.087130
59. Wouters CH, Ceuppens JL, Stevens EA. Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002 Mar–Apr;20(2):239–48.
60. Kasher-Meron M, Uziel Y, Amital H. Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report. Rheumatology (Oxford). 2009 Apr;48(4):445–6. DOI: 10.1093/rheumatology/ken492
61. Narvaez J, Diaz-Torne C, Juanola X, et al. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2009 Apr;68(4):607–8. DOI: 10.1136/ard.2008.092106
62. Feito JG, Pereda CA. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to tnf alpha antagonists. J Clin Rheumatol. 2009 Oct;15(7):363–5. DOI: 10.1097/RHU.0b013e3181ba3c6f
63. De Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158–63. DOI: 10.1002/art.1780340912
64. Cazzola M, Ponchio L, De Benedetti F, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood. 1996;87(11):4824–30.
65. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol. 1998;25(2):203–7.
66. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818–25. DOI: 10.1002/art
67. Yokota S, Miyamae T, Imagawa Т, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allerg Immunol. 2005;28(3):231–8. DOI: 10.1385/CRIAI:28:3:231
68. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31(10):2071–5.
69. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemiconset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–8. DOI: 10.1136/ard.2007.076034
70. Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. 2011 Jan;38(1):180–1. DOI: 10.3899/jrheum.100726
71. Dewitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64:1001–10. DOI: 10.1002/acr.21625
72. Kimura Y, DeWitt EM, Beukelman T, et al, and members of the Juvenile Idiopathic Arthritis Disease Specific Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Adding canakinumab to the childhood arthritis and rheumatology research alliance consensus treatment plans for systemic juvenile idiopathic arthritis. Arthritis Care Res. 2014 Sep;66(9):1430–1. DOI: 10.1002/acr.22343
73. Russo R, Katsicas M. Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy. Pediatric Rheumatology. 2011;9 Suppl 1:186.
74. Otten MH, Prince FH, Anink J, et al. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis. 2013 May;72(5):721–7. DOI: 10.1136/annrheumdis-2011-201060. Epub 2012 Jun 23.
75. Баранов АА, Алексеева ЕИ, Валиева CИ и др. Терапия генно-инженерными биологическими препаратами: эффективность и безопасность переключения. Вопросы современной педиатрии. 2014;13(1):33–51 [Baranov AA, Alekseeva EI, Valieva CI, et al. Therapy genetically engineered biological agents: efficacy and safety switch. Voprosy sovremennoi pediatrii. 2014;13(1):33–51 (In Russ.)].
76. Ramanan AV, Schneider R. Macrophage activation syndrome folloing initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003 Feb;30(2):401–3.
77. Lurati A, Teruzzi B, Salmaso A, et al. Macrophage activation syndrome (MAS) during anti-IL1 receptor therapy (anakinra) in a patient affected by systemic onset idiopathic juvenile arthritis (soJIA): A report and review of the literature. Pediatr Rheumatol Online J. 2005;3(2):79–85.
78. Kessler E, Vora S, Verbsky J. Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Pediatr Rheumatol Online J. 2012 Aug 29;10(1):30. DOI: 10.1186/1546-0096-10-30
79. Ravelli A, Schneider R, Weitzman S, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Arthritis Rheum. 2014 Mar;66 Suppl 11:S83–4. DOI: 10.1002/art.38472
80. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008 Nov;4(11):615–20. DOI: 10.1038/ncprheum0919. Epub 2008 Sep 30.
81. Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. J Rheumatol. 2010 Apr;37(4):879–80. DOI: 10.3899/jrheum.091046
82. Miettunen PM, Narendran A, Jayanthan A, et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50(2):417–9. DOI: 10.1093/rheumatology/keq218. Epub 2010 Aug 7.
83. Митенко ЕВ, Алексеева ЕИ, Денисова РВ, Слепцова ТВ. Клинический случай применения тоцилизумаба у пациентки с системным ювенильным идиопатическим артритом. Педиатрическая фармакология. 2013;(4):154–8 [Mitenko EV, Alekseeva EI, Denisova RV, Sleptsova TV. Clinical case of the use of tocilizumab in patients with systemic juvenile idiopathic arthritis. Pediatricheskaya farmakologiya. 2013;(4):154–8 (In Russ.)].
84. ReiffА. Treatment of systemic juvenile idiopathic arthritis with tocilizumab – the role of anti-interleukin-6 therapy after a decade of treatment. Biol Ther. 2012 Feb 1;2:1. DOI: 10.1007/s13554-012-0001-6
Для цитирования:
Никишина И.П., Каледа М.И. Современная фармакотерапия системного ювенильного артрита. Научно-практическая ревматология. 2015;53(1):84-93. https://doi.org/10.14412/1995-4484-2015-84-93
For citation:
Nikishina I.P., Kaleda M.I. CURRENT PHARMACOTHERAPY FOR SYSTEMIC JUVENILE ARTHRITIS. Rheumatology Science and Practice. 2015;53(1):84-93. (In Russ.) https://doi.org/10.14412/1995-4484-2015-84-93
Просмотров: 756
Послать статью по эл. почте 